These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 31921432)

  • 1. Scoring systemic lupus erythematosus (SLE) disease activity with simple, rapid outcome measures.
    Thanou A; James JA; Arriens C; Aberle T; Chakravarty E; Rawdon J; Stavrakis S; Merrill JT; Askanase A
    Lupus Sci Med; 2019; 6(1):e000365. PubMed ID: 31921432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preliminary test of the LFA rapid evaluation of activity in lupus (LFA-REAL): an efficient outcome measure correlates with validated instruments.
    Askanase A; Li X; Pong A; Shum K; Kamp S; Carthen F; Aberle T; Hanrahan L; Daly P; Giles J; Merrill JT
    Lupus Sci Med; 2015; 2(1):e000075. PubMed ID: 25861457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the Lupus Foundation of America-Rapid Evaluation of Activity in Lupus to More Complex Disease Activity Instruments As Evaluated by Clinical Investigators or Real-World Clinicians.
    Askanase AD; Nguyen SC; Costenbader K; Lim SS; Kamen D; Aranow C; Grossman J; Kapoor TM; Baker-Frost D; Aberle T; Thanou-Stavraki A; Hanrahan LM; Kim M; Merrill JT
    Arthritis Care Res (Hoboken); 2018 Jul; 70(7):1058-1063. PubMed ID: 28992399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of RNase therapy in systemic lupus erythematosus: a randomised phase 2a clinical trial of RSLV-132.
    Burge DJ; Werth VP; Boackle SA; Posada J
    Lupus Sci Med; 2024 Feb; 11(1):. PubMed ID: 38325898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Responsiveness of British Isles Lupus Assessment Group 2004 Index, Systemic Lupus Erythematosus Disease Activity Index 2000, and British Isles Lupus Assessment Group 2004 Systems Tally.
    Yee CS; Gordon C; Isenberg DA; Griffiths B; Teh LS; Bruce IN; Ahmad Y; Rahman A; Prabu A; Akil M; McHugh N; Edwards CJ; D'Cruz D; Khamashta MA; Farewell VT
    Arthritis Care Res (Hoboken); 2022 Oct; 74(10):1623-1630. PubMed ID: 33787088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Performance of systemic lupus erythematosus responder index for detecting clinician-rated responders in patients with active systemic lupus erythematosus.
    Leosuthamas P; Narongroeknawin P; Chaiamnuay S; Asavatanabodee P; Pakchotanon R
    Int J Rheum Dis; 2023 Apr; 26(4):667-672. PubMed ID: 36802112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the LFA-REAL clinician-reported outcome (ClinRO) and patient-reported outcome (PRO): prespecified analysis of the phase III ustekinumab trial in patients with SLE.
    Askanase AD; Tang W; Zuraw Q; Gordon R; Brotherton B; Merrill JT
    Lupus Sci Med; 2023 Apr; 10(1):. PubMed ID: 37012059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How should lupus flares be measured? Deconstruction of the safety of estrogen in lupus erythematosus national assessment-systemic lupus erythematosus disease activity index flare index.
    Thanou A; Chakravarty E; James JA; Merrill JT
    Rheumatology (Oxford); 2014 Dec; 53(12):2175-81. PubMed ID: 24729400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Feasibility of SLEDAI-2000 and BILAG-2004 scoring systems for assessing renal disease activity in children with lupus nephritis].
    Zhou JQ; Jiang H
    Zhongguo Dang Dai Er Ke Za Zhi; 2012 Oct; 14(10):775-9. PubMed ID: 23092572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in quality of life in relation to disease activity in systemic lupus erythematosus: post-hoc analysis of the BLISS-52 Trial.
    Jolly M; Annapureddy N; Arnaud L; Devilliers H
    Lupus; 2019 Dec; 28(14):1628-1639. PubMed ID: 31674267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Associations of the Levels of C4d-bearing Reticulocytes and High-avidity Anti-dsDNA Antibodies with Disease Activity in Systemic Lupus Erythematosus.
    Mora C; Medina-Rosas J; Santos AM; Jaimes DA; Arbeláez AM; Romero C; Cortes A; Londono J
    J Rheumatol; 2016 Sep; 43(9):1657-64. PubMed ID: 27134246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the LFA-REAL clinician-reported outcome (ClinRO) and patient-reported outcome (PRO): data from the Peruvian Almenara Lupus Cohort.
    Ugarte-Gil MF; Gamboa-Cardenas RV; Reátegui-Sokolova C; Pimentel-Quiroz VR; Zeña-Huancas P; Elera-Fitzcarrald C; Garcia-Hirsh S; Gil L; Pastor-Asurza CA; Rodriguez-Bellido Z; Merrill J; Askanase AD; Alarcon G; Perich-Campos RA
    Lupus Sci Med; 2020 Oct; 7(1):. PubMed ID: 33046557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials.
    Manzi S; Sánchez-Guerrero J; Merrill JT; Furie R; Gladman D; Navarra SV; Ginzler EM; D'Cruz DP; Doria A; Cooper S; Zhong ZJ; Hough D; Freimuth W; Petri MA;
    Ann Rheum Dis; 2012 Nov; 71(11):1833-8. PubMed ID: 22550315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Which outcome measures in SLE clinical trials best reflect medical judgment?
    Thanou A; Chakravarty E; James JA; Merrill JT
    Lupus Sci Med; 2014; 1(1):e000005. PubMed ID: 25396057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the validity and sensitivity to change of 5 activity indices in systemic lupus erythematosus.
    Ward MM; Marx AS; Barry NN
    J Rheumatol; 2000 Mar; 27(3):664-70. PubMed ID: 10743805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Organ system improvements in Japanese patients with systemic lupus erythematosus treated with belimumab: A subgroup analysis from a phase 3 randomized placebo-controlled trial.
    Tanaka Y; Bass D; Chu M; Egginton S; Ji B; Roth D
    Mod Rheumatol; 2020 Mar; 30(2):313-320. PubMed ID: 31199180
    [No Abstract]   [Full Text] [Related]  

  • 17. Novel evidence-based systemic lupus erythematosus responder index.
    Furie RA; Petri MA; Wallace DJ; Ginzler EM; Merrill JT; Stohl W; Chatham WW; Strand V; Weinstein A; Chevrier MR; Zhong ZJ; Freimuth WW
    Arthritis Rheum; 2009 Sep; 61(9):1143-51. PubMed ID: 19714615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus.
    Furie RA; Bruce IN; Dörner T; Leon MG; Leszczyński P; Urowitz M; Haier B; Jimenez T; Brittain C; Liu J; Barbey C; Stach C
    Rheumatology (Oxford); 2021 Nov; 60(11):5397-5407. PubMed ID: 33956056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 and TULIP-2 trials.
    Morand EF; Furie RA; Bruce IN; Vital EM; Dall'Era M; Maho E; Pineda L; Tummala R
    Lancet Rheumatol; 2022 Apr; 4(4):e282-e292. PubMed ID: 38288923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.
    Petri MA; van Vollenhoven RF; Buyon J; Levy RA; Navarra SV; Cervera R; Zhong ZJ; Freimuth WW;
    Arthritis Rheum; 2013 Aug; 65(8):2143-53. PubMed ID: 23754628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.